Filana Therapeutics (FLNA) vs Nasus Pharma (NSRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nasus Pharma (NSRX) has outperformed Filana Therapeutics (FLNA) over the past year, losing 50.1% versus a loss of 76.1%. Nasus Pharma is the larger company by market cap ($42.5 million vs $39.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FLNA | NSRX |
|---|---|---|
| Share price | $0.8136 | $3.63 |
| Market cap | $39.30M | $42.52M |
| 1-day change | -0.26% | -3.84% |
| YTD return | -58.80% | -60.33% |
| 1-year return | -76.15% | -50.07% |
| 5-year return | -98.36% | — |
| EPS (TTM) | $-0.87 | $-1.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.98 | $9.50 |
| 52-week low | $0.67 | $1.98 |
| Distance from 52-week high | -83.66% | -61.79% |
| Analyst consensus | none | buy |
| Avg. price target upside | +698.92% | +441.87% |
| Average volume | 2.03M | 16.09K |
| Shares outstanding | 48.31M | 11.71M |
| Employees | 17 | 7 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - General |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NSRX has outperformed FLNA by 26.1 percentage points over the past year.
About Filana Therapeutics
FLNA stock →Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood.
Healthcare · Biotechnology · 17 employees
About Nasus Pharma
NSRX stock →Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats.
Healthcare · Drug Manufacturers - General · 7 employees
FLNA vs NSRX FAQ
Which is bigger, Filana Therapeutics or Nasus Pharma?
Nasus Pharma (NSRX) is larger, with a market capitalization of $42.52M compared with $39.30M for Filana Therapeutics (FLNA).
Which stock has performed better over the past year, FLNA or NSRX?
NSRX returned -50.07% over the past 12 months, compared with -76.15% for FLNA (price return, excluding dividends). Past performance does not predict future results.
Are Filana Therapeutics and Nasus Pharma in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for Filana Therapeutics and Drug Manufacturers - General for Nasus Pharma.